Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 12, 2005, Pages 1022-1030

  Gabriel, Don A ^a   Shea, Thomas C ^a   Serody, Jonathan S ^a   Moore, Dominic T ^a   Kirby, Suzanne L ^a   Harvey, Donald ^a   Krasnov, Carol ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Amifostine; Mucositis; Total parenteral nutrition

Indexed keywords

ACICLOVIR; AMIFOSTINE; ANTIEMETIC AGENT; CALCIUM DERIVATIVE; CARBOPLATIN; CEFEPIME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; NARCOTIC AGENT; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CELL PROTECTION; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; EXPERIENCE; EXPERIMENTAL DESIGN; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PLEURA FLUID; RECURRENT CANCER; THROMBOCYTE; TOTAL PARENTERAL NUTRITION; UROGENITAL TRACT INFECTION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AMIFOSTINE; CYTOPROTECTION; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NARCOTICS; PARENTERAL NUTRITION; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 28744455216     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.08.033     Document Type: Article

References (58)

1. Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther. 2003;18:853-874
2. Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21-36
3. Eisen D, Essell J, Broun ER. Oral cavity complications of bone marrow transplantation. Semin Cutan Med Surg. 1997;16:265-272
4. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993;20:1493-1502
5. Shea TC, Bruner R, Wiley JM, et al. An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2003;9:443-452
6. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000;110:292-299
7. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72:1612-1617
8. Bellm LA, Cunningham G, Durnell L, et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board. Cancer Invest. 2002;20:793-800
9. Donaldson GW. The factorial structure and stability of the McGill Pain Questionnaire in patients experiencing oral mucositis following bone marrow transplantation. Pain. 1995;62: 101-109
10. McGuire DB, Yeager KA, Dudley WN, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: Data from a pilot study. Cancer Nurs. 1998;21:385-393
11. McGuire DB, Peterson DE, Muller S, Owen DC, Slemmons MF, Schubert MM. The 20 item oral mucositis index: Reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest. 2002;20:893-903
12. Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer. 1992;69:2469-2477
13. Tardieu C, Cowen D, Thirion X, Franquin JC. Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer B Oral Oncol. 1996; 32B: 381-387
14. Walsh LJ, Hill G, Seymour G, Roberts A. A scoring system for the quantitative evaluation of oral mucositis during bone marrow transplantation. Spec Care Dentist. 1990;10:190-195
15. Phillips GL II. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol. 2002;29:53-56
16. Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 2003;30:76-83
17. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112
18. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345
19. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: Differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplant. 1997;19:557-563
20. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol. 1999; 85:22 3776-3785
21. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol. 1994;12: 1169-1176
22. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with highdose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117- 122
23. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999;85:2103-2113
24. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0, DCTD, NCI, NIH, DHHS. March 1998. Available at: http://ctep.cancer.gov/reporting/ctc.html Accessed Sep 6, 2005.
25. Hartmann JT, von Vangerow A, Fels LM, et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer. 2001;84:313-320
26. Chauncey TR, Gooley TA, Lloid ME, et al. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol. 2000;23:406-411
27. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy- induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739-747
28. Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2002;30:769-775
29. Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study. Br J Haematol. 2000;110:300-307
30. Patriarca F. Amifostine pretreatment for protection against melphalan plus busulfan-induced toxicity in high-dose therapy for multiple myeloma patients [abstract]. Blood 1999; 94 (suppl 1): 404b
31. Donnelly JP, Muus P, Horrevorts AM, Sauerwein RW, De Pauw BE. Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteraemia in allogeneic bone marrow transplant recipients. Scand J Infect Dis. 1993;25:43-50
32. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531-1539
33. Garfunkel AA, Tager N, Chausu S, Chausu G, Haze C, Galili D. Oral complications in bone marrow transplantation patients: Recent advances. Isr J Med Sci. 1994;30:120-124
34. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin. 2001;51:290-315
35. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001;33:338-343
36. Lucas VS, Beighton D, Roberts GJ, Challacombe SJ. Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect. 1997;35:135-141
37. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275-2281
38. Alvarado Y, Bellm LA, Giles FJ. Oral mucositis: Time for more studies. Hematology. 2002;7:281-289
39. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview. Bone Marrow Transplant. 2000;25:1269-1278
40. Stiff P. Mucositis associated with stem cell transplantation: Current status and innovative approaches to management. Bone Marrow Transplant 2001; 27 (suppl 2): S3-S11
41. Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf. 1993;9:185-195
42. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: A review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:39-44
43. Sonis ST. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39-43
44. Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13: 380-389
45. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293:293-297
46. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis. 2003;3:405-412
47. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene. 2000;19:1206-1214
48. Kataoka Y, Murley JS, Khodarev NN, Weichselbaum RR, Grdina DJ. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int J Radiat Oncol Biol Phys. 2002;53:180-189
49. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ. Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med. 2001;30:1426-1439
50. Bennett CL, Lane D, Stinson T, Glatzel M, Büntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001;19:107-113
51. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201-2205
52. Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 1994; 30B: 93-97
53. Cowen D, Tardieu C, Schubert M, et al. Low energy heliumneon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. Int J Radiat Oncol Biol Phys. 1997;38:697-703
54. Whelan HT, Connelly JF, Hodgson BD, et al. NASA lightemitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg. 2002; 20:319-324
55. Antin JH, Lee SJ, Neuberg D, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:373-377
56. Bez C, Demarosi F, Sardella A, et al. GM-CSF mouthrinses in the treatment of severe oral mucositis: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:311-315
57. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452-1458
58. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598